IDEXX LABORATORIES INC /DE — Director's Dealing 2020

Aug 18, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2020-08-14

Reporting Person: MCKEON BRIAN P (Executive VP & CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-08-14	Common Stock	M	8790	$43.68	Acquired	58386	Direct
2020-08-14	Common Stock	M	37836	$53.185	Acquired	96222	Direct
2020-08-14	Common Stock	M	37098	$62	Acquired	133320	Direct
2020-08-14	Common Stock	S	28997	$377.8422	Disposed	104323	Direct
2020-08-14	Common Stock	S	37209	$379.2013	Disposed	67114	Direct
2020-08-14	Common Stock	S	14469	$380.1204	Disposed	52645	Direct
2020-08-14	Common Stock	S	3049	$381.4754	Disposed	49596	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-08-14	Non-Qualified Stock Option (right-to-buy)	$43.68	M	8790	Disposed	2023-05-07	Common Stock (8790)	Direct
2020-08-14	Non-Qualified Stock Option (right-to-buy)	$53.185	M	37836	Disposed	2023-12-31	Common Stock (37836)	Direct
2020-08-14	Non-Qualified Stock Option (right-to-buy)	$62	M	37098	Disposed	2024-02-13	Common Stock (37098)	Direct

Footnotes

F1: Represents the weighted average price of the shares sold ranging from a low of $377.49 to a high of $378.43 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F2: Represents the weighted average price of the shares sold ranging from a low of $378.63 to a high of $379.614 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F3: Represents the weighted average price of the shares sold ranging from a low of $379.676 to a high of 380.674 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F4: Represents the weighted average price of the shares sold ranging from a low of $380.792 to a high of $381.79 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F5: Grant of option to buy 4,395 shares of IDEXX Laboratories, Inc. common stock that became exercisable in one installment on May 8, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F6: Grant of option to buy 18,918 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning on January 1, 2015 without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F7: Grant of option to buy 18,549 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning February 14, 2015 without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F8: Not applicable.